Subscribe To
viracta therapeutics to present at the jefferies healthcare conference
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) — viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision onc...
May 31, 2023, 8:15 pm
viracta therapeutics to present at the rbc capital markets global healthcare conference
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision onco...
May 11, 2023, 4:05 pm
viracta therapeutics to present at the stifel 2023 targeted oncology days
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) — viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision o...
April 19, 2023, 8:30 pm
viracta therapeutics to present at the 33rd annual oppenheimer healthcare conference
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision on...
March 8, 2023, 4:05 pm
viracta therapeutics announces first clinical response in epstein-barr virus-positive (ebv+) solid tumor setting and outlines key 2023 clinical objectives
Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV+ recurrent/metastatic (R/M) nasopharyngeal...
January 8, 2023, 6:00 pm
viracta therapeutics announces preliminary dose-ranging data from the phase 1b/2 trial of nana-val in advanced epstein-barr virus-positive (ebv+) solid tumors at the esmo immuno-oncology congress
Data from first two dose levels of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal carcinoma support continued dose escalation to d...
November 30, 2022, 11:10 pm
viracta therapeutics to present at the 21st annual needham virtual healthcare conference
SAN DIEGO , April 7, 2022 /PRNewswire/ -- viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision onco...
April 7, 2022, 10:13 am